Pazopanib for the treatment of metastatic renal cell carcinoma
about
Pazopanib in the treatment of advanced renal cell carcinomaOvarian cancer standard of care: are there real alternatives?Identification of patient-specific and tumor-shared T cell receptor sequences in renal cell carcinoma patientsEfficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case seriesIn comparative analysis of multi-kinase inhibitors for targeted medulloblastoma therapy pazopanib exhibits promising in vitro and in vivo efficacy.Tumour vasculature targeting agents in hybrid/conjugate drugs.Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy.PharmGKB summary: pazopanib pathway, pharmacokinetics.Overview of fundamental study of pazopanib in cancer.Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review.Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study.Synthesis, QSAR studies, and metabolic stability of novel 2-alkylthio-4-chloro-N-(5-oxo-4,5-dihydro-1,2,4-triazin-3-yl)benzenesulfonamide derivatives as potential anticancer and apoptosis-inducing agents.Synthesis, Molecular Structure, Anticancer Activity, and QSAR Study of N-(aryl/heteroaryl)-4-(1H-pyrrol-1-yl)Benzenesulfonamide Derivatives.Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients.
P2860
Q26770413-5A2330C9-785F-48F1-A025-7F169929C83EQ26862249-5034D70A-8A21-4E13-B3EB-108EAA384778Q30313444-8FA741CA-DC79-4DA2-9B31-F7920D12DF62Q33276267-70A2E666-882E-4723-B6A8-C25C71B433F8Q34334533-9D6FCB7D-42E3-45AF-9BB5-4CCDF82BCEC8Q38094627-A8DE5BBA-1C0F-45BA-A7BA-FD9619EE4E3BQ38286128-507BEA81-F98B-465A-B6A1-D8C8E1F15042Q38693146-9B31FDCD-D7F3-4ED5-978E-3B5092A7B9BDQ38696525-42690A8F-E431-416A-A220-95F42BF27CDCQ39067386-5264EB4A-FAB4-4162-9B5A-7DF68F8249D4Q40219977-0E76D02D-2B52-4E54-8314-F82C1D7D7F9BQ47181684-12F5260A-6710-4431-A3AC-A334A2A71535Q54975597-69B946F4-6CB5-47D4-BBAA-1B0D6BF97C99Q55476332-8C79FEAE-146B-449D-8136-9CABFF055A17
P2860
Pazopanib for the treatment of metastatic renal cell carcinoma
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Pazopanib for the treatment of metastatic renal cell carcinoma
@ast
Pazopanib for the treatment of metastatic renal cell carcinoma
@en
Pazopanib for the treatment of metastatic renal cell carcinoma
@nl
type
label
Pazopanib for the treatment of metastatic renal cell carcinoma
@ast
Pazopanib for the treatment of metastatic renal cell carcinoma
@en
Pazopanib for the treatment of metastatic renal cell carcinoma
@nl
prefLabel
Pazopanib for the treatment of metastatic renal cell carcinoma
@ast
Pazopanib for the treatment of metastatic renal cell carcinoma
@en
Pazopanib for the treatment of metastatic renal cell carcinoma
@nl
P3181
P1476
Pazopanib for the treatment of metastatic renal cell carcinoma
@en
P2093
Amy M Pick
Kelly K Nystrom
P304
P3181
P356
10.1016/J.CLINTHERA.2012.01.014
P407
P577
2012-03-01T00:00:00Z